Psychopharmacology today: Where are we and where do we go from Here

Mens Sana Monographs

Volumn 8, Issue 1, 2010, Pages 6-16

  Schwartz, Thomas L ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Pharmacodynamics; Prescribing practices; Psychiatric outcomes; Psychopharmacology

Indexed keywords

EID: 75649151234     PISSN: 09731229     EISSN: 19984014     Source Type: Journal    
DOI: 10.4103/0973-1229.58816     Document Type: Review

References (21)

1. American Psychiatric Association, (2000), Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition Text Revision. Washington DC: American Psychiatric Publishing.
2. Bourin M., Prica C., (2009), Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression. Current Pharmaceutical Design. 15(14), p1675-1682.
3. Canuso C.M., Dirks B., Carothers J., Kosik-Gonzalez C,. Bossie C.A., Zhu Y., Damaraju C.V., Kalali A.H., Mahmoud R., (2009), Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia, American Journal of Psychiatry, 166(6), p691-701.
4. Cohen J., (1977), Statistical Power Analysis for the Behavioral Sciences, New York: Academic Press.
5. DeBartolomeis A., Fiore G., Iasoveli F., (2005), Dopamine-glutamate interaction and antipsychoticsmechanism of action: implication for new pharmacological strategies in psychosis. Current Pharmaceutical Design. 11:351-359.
6. Greenberg R.P., (2004), Essential ingredients for successful psychotherapy: Effect of common factors. In: Dewan M., Steenbarger B., Greenberg, S. The Art and Science of Brief Psychotherapies- A Practitioner's Guide. Washington DC: American Psychiatric Publishing
7. Gregory R. J., Chlebowski S., Kang D., Remen A. L., Soderberg M. G., Stepkovitch J., Virk S., (2008), A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder, Psychotherapy: Theory, Research, Practice, Training, 45, p28-41.
8. Keck P.E., Orsulak P.J., Cutler A.J., Sanchez R., Torbeyns A., Marcus R.N., McQuade R.D., Carson W.H., (2009), Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study, Journal of Affective Disorders, 112(1-3), p36-49.
9. Liang Y., Shaw A.M., Boules M., Briody S., Robinson J., Oliveros A., Blazar E., Williams K., Zhang Y., Carlier P.R., Richelson E., (2008), Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1- phenylpropan-1-ol (PRC200-SS), Journal of Pharmacology & Experimental Therapeutics, 327(2), p573-583.
10. Lynch T.R., Trost W.T. Salsman N., Linehan M.M., (2007), Dialectical behavior therapy for borderline personality disorder, Annual Review of Clinical Psychology, 3, p181-205.)
11. Rutherford B.R., Rose S.A., Sneed J.R., Roose S.P., (2009), Study design affects participant expectations: a survey, Journal of Clinical Psychopharmacology, 29(2), p179-181.
12. Schwartz T.L., Rashid A.,(2007), Augmentation and Combination Pharmacotherapy trends in major depressive disorder: Results of a brief survey of psychiatrists Pharmacy &Therapeutics, 32(1), p28-31.
13. Schwartz T.L., Thase M., Stormon L., (2006), Treatment Outcomes with Acute Pharmacotherapy/ Psychotherapy. In [Schwartz T. and Petersen T.] Depression: Treatment Strategies and Management, 1st Ed., New York: Taylor and Francis.
14. Stahl S M., (2000), The 7 habits of highly effective psycho pharmacologists, Part 1, Journal of Clinical Psychiatry, 61(4), p242-3.
15. Stahl S.M., (2008), Stahl's Essential Psychopharmacology: NeuroScientific Basis and Practical Approaches, 3rd Ed. Cambridge: Cambridge University Press.
16. Szegedi A., Jansen W.T., van Willigenburg A.P., van der Meulen E., Stassen H.H., Thase M.E., (2009), Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients, Journal of Clinical Psychiatry, 70(3), p344-353.
17. Thase M.E., (2003), Evaluating antidepressant therapies: remission as the optimal outcome, Journal of Clinical Psychiatry, 64 Suppl 13, p18-25.
18. Trivedi M.H., Rush A.J., Wisniewski S.R., et al., (2006), Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice, Am J Psychiatry, 163 (1), p28-40.
19. Walsh B.T, Seidman S.N, Sysko R., Gould M., (2002), Placebo response in studies of major depression: variable, substantial, and growing, JAMA, 287, p1840-1847.
20. Zajecka JM., Goldstein C., (2009), Combining Medication to Achieve Remission. In: [ Schwartz T. and Petersen T. eds] Depression:Treatment Strategies and Management, 2nd Ed. New York: Informa.
21. Zimmerman M., McGlinchey J.B., Chelminski I., (2009), Measurement Based Care and Outcome Measures: Implications for Practice. In [Schwartz T. and Petersen T eds] Treatment Strategies and Management, 2nd Ed. New York: Informa